RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody combo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 3 trial tests an experimental drug, odronextamab, combined with lenalidomide in people with follicular or marginal zone lymphoma that has returned or not responded to treatment. The study first checks safety and dosing, then compares the new combo against the standard …
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune cell combo tackles tough lymphoma
Disease control Recruiting nowThis study tests whether a special type of immune cell (ONC-PluReceptor NK cells) given with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 who have alrea…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail of four drugs hopes to tackle tough lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see how many patients achieve a complete r…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for lymphoma patients: mosunetuzumab under review
Disease control Recruiting nowThis study looks back at medical records of 25 adults with follicular lymphoma that returned or didn't respond to at least two prior treatments. All patients received mosunetuzumab through a compassionate use program. Researchers want to see how well the drug works and what side …
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC